GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix ...
PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...
GlaxoSmithKline places its shingles vaccine ... Another company developing a vaccine for herpes zoster is US biotech Curevo Vaccine, whose adjuvanted subunit vaccine CRV-101 is in early-stage ...
GSK has launched it's Shingles vaccine in Malaysia and here's all you need to know about it. From what it is, to the side ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...
Shingrix [Herpes Zoster vaccine (recombinant, AS01 B ix adjuvanted)] is a non-live, recombinant subunit vaccine indicated for the prevention of shingles (herpes zoster) and, in some markets, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback